Ong KL, et al. - This study was undertaken to determine if levels of FGF21 predict major cardiovascular events (MCVE) in atorvastatin-treated patients. After 8 weeks of atorvastatin 10 mg/day, 10,001 patients with the stable coronary disease were randomized for a median of 4.9 years to 10 mg or 80 mg/day of atorvastatin in the TNT trial. Researchers analyzed data from 1996 patients with randomized FGF21 plasma levels. Findings suggested an association of higher plasma FGF21 levels with higher cardiovascular disease (CVD) risk in statin-treated high-risk patients. Higher atorvastatin dose is related to reduced FGF21 levels. Changes in FGF21 levels over 1 year were not associated with the subsequent risk of MCVE. Outcomes revealed that FGF21 provides an increase in the prediction of CVD risk in statin-treated patients.